Form D1: Clinician Diagnosis

Similar documents
Form A3: Subject Family History

UDS version 3 Summary of major changes to UDS form packets

Dementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota

DISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT

DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD

The frontotemporal dementia spectrum what the general physician needs to know Dr Jonathan Rohrer

! slow, progressive, permanent loss of neurologic function.

FRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS

Mild Cognitive Impairment (MCI)

3/7/2017. Alzheimer s and Dementia Research: An Advanced Discussion. Alzheimer s and Dementia Research: An Advanced Discussion

Perspectives on Frontotemporal Dementia and Primary Progressive Aphasia

Sandra Weintraub, PhD Clinical Core Leader and Professor

Do not copy or distribute without permission. S. Weintraub, CNADC, NUFSM, 2009

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada

NACC Minimum Data Set (MDS) Public Data Element Dictionary

NCRAD. Single Gene Implicated in FTD/ALS UCSF Memory and Aging Center, San Francisco, California

Comments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic Guidelines? The Debate Continues

Objectives. RAIN Difficult Diagnosis 2014: A 75 year old woman with falls. Case History: First visit. Case History: First Visit

Dementia Past, Present and Future

Objectives. Objectives continued: 3/24/2012. Copyright Do not distribute or replicate without permission 1

Non Alzheimer Dementias

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

LANGUAGE AND PATHOLOGY IN FRONTOTEMPORAL DEGENERATION

I do not have any disclosures

Diagnosis and Treatment of Alzhiemer s Disease

2016 Programs & Information

Diagnosis before NIA AA The impact of FDG PET in. Diagnosis after NIA AA Neuropathology and PET image 2015/10/16

Moving Targets: An Update on Diagnosing Dementia in the Clinic

Dementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology

Dementia: A Comprehensive Update Neuroimaging, CSF, and genetic biomarkers in dementia

Clinical Diagnosis. Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV)

Frontotemporal dementia:

Recent publications using the NACC Database. Lilah Besser

Ruolo dei biomarcatori come criterio di supporto nella diagnostica delle demenze ad esordio precoce

Regulatory Challenges across Dementia Subtypes European View

White matter hyperintensities correlate with neuropsychiatric manifestations of Alzheimer s disease and frontotemporal lobar degeneration

Clinical Genetics & Dementia

What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia

Assessing and Managing the Patient with Cognitive Decline

NIH Public Access Author Manuscript Semin Neurol. Author manuscript; available in PMC 2014 November 14.

United Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline

DSM-5 MAJOR AND MILD NEUROCOGNITIVE DISORDERS (PAGE 602)

Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases

A Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies

Dementia and Healthy Ageing : is the pathology any different?

Early Onset Dementia From the background to the foreground

FTD basics! Etienne de Villers-Sidani, MD!

Diagnosing Dementia: Signs & symptoms, differential diagnosis of common dementias, and non-degenerative memory loss

Imaging of Alzheimer s Disease: State of the Art

Paper Title Theme Presentation Type Poster Presentatio n Day

Delirium & Dementia. Nicholas J. Silvestri, MD

Imaging in Dementia:

Part 2: Early detection, assessment and treatment in relation to the new guidelines. Christopher Patterson McMaster University

Prof Tim Anderson. Neurologist University of Otago Christchurch

DEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease

Initial Visit Packet Forms

Update on functional brain imaging in Movement Disorders

Clinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA

brain MRI for neuropsychiatrists: what do you need to know

NACC Minimum Data Set (MDS) Data Element Dictionary

The Ethics of Working with Aging Donors

I IADL. See Instrumental activities of daily living (IADL) Idiopathic rapid eye movement sleep behavior disorder (Idiopathic RBD), 136

Alzheimer s Disease Neuroimaging Initiative

Differential Diagnosis

Diagnosis and management of non-alzheimer dementias. Melissa Yu, M.D. Department of Neurology

American Medical Association, American Academy of Neurology Institute and American Psychiatric Association (2016)

Alzheimer s Disease without Dementia

Presenter Disclosure Information. I have no financial relationships to disclose:

Improving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018

The Aging Brain The Aging Brain

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Mild cognitive impairment A view on grey areas of a grey area diagnosis

Mild Cognitive Impairment

Frontotemporal Dementia: Towards better diagnosis. Frontotemporal Dementia. John Hodges, NeuRA & University of New South Wales, Sydney.

CNADC. S. Weintraub, CNADC, Northwestern FSM, 2011 DO NOT COPY OR DISTRIBUTE WITHOUT AUTHORʼS PERMISSION

Dementia: It s Not Always Alzheimer s

Visual Dysfunction in Alzheimer s Disease and Parkinson s Disease

Confronting the Clinical Challenges of Frontotemporal Dementia

Rarer causes of dementia

UCSF Memory and Aging Center 2016

The added value of the IWG-2 diagnostic criteria for Alzheimer s disease

New diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist

Clinical classification of dementias, particularly in

Cognitive Ability (Decline) & Social Isolation

FTD/PPA Caregiver Education Conference March 11, 2011

NACC Neuropathology (NP) Diagnosis Coding Guidebook

The ABCs of Dementia Diagnosis

Dr Roger Cable NHS Dumfries and Galloway

Differentiating Dementia Diagnoses

Type 2 Diabetes and Brain Disease in Older Adults. Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky

1 in 3 seniors dies with Alzheimer s or another dementia.

review of existing studies on ASL in dementia Marion Smits, MD PhD

September 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by

Vascular Dementia. Laura Pedelty, PhD MD The University of Illinois at Chicago and Jesse Brown VA Medical Center

Biomarkers: Translating Research into Clinical Practice

Imaging biomarkers for Parkinson s disease

Differential Diagnosis of Hypokinetic Movement Disorders

Personal Reflections on the Design and Delivery of Services to Those with Cognitive Disorders

Cognitive Screening in Risk Assessment. Geoffrey Tremont, Ph.D. Rhode Island Hospital & Alpert Medical School of Brown University.

Memory Matters: Learning Objectives: Synapses, Age, and Health. Neuronal Synapses DISCLOSURE DECLARATION. Cognition and Normal Aging

Transcription:

Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician. For additional clarification and examples, see UDS Coding Guidebook for Initial Visit Packet, Form D. Check only one box per question. This form is divided into three main sections: Section Section 2 Section 3 Cognitive and behavioral status: Normal cognition / MCI / dementia and dementia syndrome Biomarkers, imaging, and genetics: Neurodegenerative imaging and CSF biomarkers, imaging evidence for CVD, and known genetic mutations for AD and FTLD Etiological diagnoses: presumed etiological diagnoses for the cognitive disorder. Diagnosis method responses in this form are based on diagnosis by: A single clinician 2 A formal consensus panel 3 Other (e.g., two or more clinicians or other informal group) SECTION : Cognitive and behavioral status 2. Does the subject have normal cognition (global CDR= and/or neuropsychological testing within normal range) and normal behavior (i.e., the subject does not exhibit behavior sufficient to diagnose MCI or dementia due to FTLD or LBD)? (Continue to Question 3) Yes (SKIP to Question 6) All-cause dementia The subject has cognitive or behavioral (neuropsychiatric) symptoms that meet all of the following criteria: Interfere with ability to function as before at work or at usual activities? Represent a decline from previous levels of functioning? Are not explained by delirium or major psychiatric disorder? Include cognitive impairment detected and diagnosed through a combination of ) history-taking and 2) objective cognitive assessment (bedside or neuropsychological testing)? AND Impairment in one* or more of the following domains. Impaired ability to acquire and remember new information Impaired reasoning and handling of complex tasks, poor judgment Impaired visuospatial abilities Impaired language functions Changes in personality, behavior, or comportment * In the event of single-domain impairment (e.g., language in PPA, behavior in bvftd, posterior cortical atrophy), the subject must not fulfill criteria for MCI. 3. Does the subject meet the criteria for dementia? (skip to Question 5) Yes (Continue to Question 4) UDS Version 3., March 25 Page of 7

4. If the subject meets criteria for dementia, answer Questions 4a 4f below and then SKIP TO QUESTION 6. Based entirely on the history and examination (including neuropsychological testing), what is the cognitive/behavioral syndrome? Select one or more as Present; all others will default to Absent in the NACC database. Dementia syndrome Present 4a. Amnestic multidomain dementia syndrome 4b. Posterior cortical atrophy syndrome (or primary visual presentation) 4c. Primary progressive aphasia (PPA) syndrome 4c. Meets criteria for semantic PPA 2 Meets criteria for logopenic PPA 3 Meets criteria for nonfluent/agrammatic PPA 4 PPA other/not otherwise specified 4d. Behavioral variant FTD (bvftd) syndrome 4e. Lewy body dementia syndrome 4f. Non-amnestic multidomain dementia, not PCA, PPA, bvftd, or DLB syndrome 5. If the subject does not have normal cognition or behavior and is not clinically demented, indicate the type of cognitive impairment below. MCI CORE CLINICAL CRITERIA Is the subject, the co-participant, or a clinician concerned about a change in cognition compared to the subject s previous level? Is there impairment in one or more cognitive domains (memory, language, executive function, attention, and visuospatial skills)? Is there largely preserved independence in functional abilities (no change from prior manner of functioning or uses minimal aids or assistance)? Select one syndrome from 5a 5e as being Present (all others will default to Absent in the NACC database), and then continue to Question 6. If you select MCI below, it should meet the MCI core clinical criteria outlined above. Type Present Affected domains No Yes 5a. Amnestic MCI, single domain (amci SD) 5b. Amnestic MCI, multiple domains (amci MD) Check YES for at least one additional domain (besides memory): 5b. Language 5b2. Attention 5b3. Executive 5b4. Visuospatial UDS (v3., March 25) Initial Visit Form D: Clinician Diagnosis Page 2 of 7

Select one syndrome from 5a 5e as being Present (all others will default to Absent in the NACC database), and then continue to Question 6. If you select MCI below, it should meet the MCI core clinical criteria outlined above. Type Present Affected domains No Yes 5c. Non-amnestic MCI, single domain (namci SD) Check yes to indicate the affected domain: 5c. Language 5c2. Attention 5c3. Executive 5c4. Visuospatial 5d. Non-amnestic MCI, multiple domains (namci MD) Check yes for at least two domains: 5d. Language 5d2. Attention 5d3. Executive 5d4. Visuospatial 5e. Cognitively impaired, not MCI SECTION 2: Biomarkers, imaging, and genetics Section 2 must be completed for all subjects. 6. Indicate neurodegenerative biomarker status, using local standards for positivity. Biomarker findings No Yes Unknown/ not assessed 6a. Abnormally elevated amyloid on PET 8 6b. Abnormally low amyloid in CSF 8 6c. FDG-PET pattern of AD 8 6d. Hippocampal atrophy 8 6e. Tau PET evidence for AD 8 6f. Abnormally elevated CSF tau or ptau 8 6g. FDG-PET evidence for frontal or anterior temporal hypometabolism for FTLD 8 6h. Tau PET evidence for FTLD 8 6i. Structural MR evidence for frontal or anterior temporal atrophy for FTLD 6j. Dopamine transporter scan (DATscan) evidence for Lewy body disease 8 8 6k. Other (SPECIFY): UDS (v3., March 25) Initial Visit Form D: Clinician Diagnosis Page 3 of 7

7. Is there evidence for cerebrovascular disease (CVD) on imaging? Imaging findings No Yes Unknown/ not assessed 7a. Large vessel infarct(s) 8 7b. Lacunar infarct(s) 8 7c. Macrohemorrhage(s) 8 7d. Microhemorrhage(s) 8 7e. Moderate white-matter hyperintensity (CHS score 5 6) 8 7f. Extensive white-matter hyperintensity (CHS score 7 8+) 8 8. Does the subject have a dominantly inherited AD mutation (PSEN, PSEN2, APP)? Yes 9 Unknown/not assessed 9. Does the subject have a hereditary FTLD mutation (e.g., GRN, VCP, TARBP, FUS, C9orf72, CHMP2B, MAPT)? Yes 9 Unknown/not assessed. Does the subject have a hereditary mutation other than an AD or FTLD mutation? Yes (SPECIFY): 9 Unknown/not assessed SECTION 3: Etiologic diagnoses Section 3 must be filled out for all subjects. Indicate presumptive etiologic diagnoses of the cognitive disorder and whether a given diagnosis is a primary, contributing, or non-contributing cause of the observed impairment, based on the clinician s best judgment. Select one or more diagnoses as Present; all others will default to Absent in the NACC database. Only one diagnosis should be selected as = Primary. For subjects with normal cognition: Indicate the presence of any diagnoses by marking Present, and leave the questions on whether the diagnosis was primary, contributing, or non-contributing blank. Subjects with positive biomarkers but no clinical symptoms of Alzheimer s disease, Lewy body disease, or frontotemporal lobar degeneration should not have these diagnoses marked as Present. Instead, the biomarker data from Section 2 can be used to identify the presence of preclinical disease. Etiologic diagnoses. Alzheimer s disease a 2 3 2. Lewy body disease 2a 2 3 2b. Parkinson s disease 3. Multiple system atrophy 3a 2 3 4. Frontotemporal lobar degeneration 4a. Progressive supranuclear palsy (PSP) 4a 2 3 4b. Corticobasal degeneration (CBD) 4b 2 3 4c. FTLD with motor neuron disease 4c 2 3 4d. FTLD NOS 4d 2 3 4e. If FTLD (Questions 4a 4d) is Present, specify FTLD subtype: Tauopathy 2 TDP- 43 proteinopathy 3 Other (SPECIFY): 9 Unknown UDS (v3., March 25) Initial Visit Form D: Clinician Diagnosis Page 4 of 7

SECTION 3: Etiologic diagnoses (cont.) Section 3 must be filled out for all subjects. Indicate presumptive etiologic diagnoses of the cognitive disorder and whether a given diagnosis is a primary, contributing, or non-contributing cause of the observed impairment, based on the clinician s best judgment. Select one or more diagnoses as Present; all others will default to Absent in the NACC database. Only one diagnosis should be selected as =Primary. For subjects with normal cognition: Indicate the presence of any diagnoses by selecting =Present, and leave the questions on whether the diagnosis was primary, contributing, or non-contributing blank. Subjects with positive biomarkers but no clinical symptoms of Alzheimer s disease, Lewy body disease, or frontotemporal lobar degeneration should not have these diagnoses selected as Present. Instead, the biomarker data from Section 2 can be used to identify the presence of preclinical disease. Etiologic diagnoses 5. Vascular brain injury (based on clinical or imaging evidence) If significant vascular brain injury is absent, SKIP TO QUESTION 6. 5a 2 3 5b. Previous symptomatic stroke? (SKIP TO QUESTION 5c) Yes 5b. Temporal relationship between stroke and cognitive decline? Yes 5b2. Confirmation of stroke by neuroimaging? Yes 9 Unknown; no relevant imaging data available 5c. Is there imaging evidence of cystic infarction in cognitive network(s)? Yes 9 Unknown; no relevant imaging data available 5d. Is there imaging evidence of cystic infarction, imaging evidence of extensive white matter hyperintensity (CHS grade 7 8+), and impairment in executive function? Yes 9 Unknown; no relevant imaging data available 6. Essential tremor 6a 2 3 7. Down syndrome 7a 2 3 8. Huntington s disease 8a 2 3 9. Prion disease (CJD, other) 9a 2 3 UDS (v3., March 25) Initial Visit Form D: Clinician Diagnosis Page 5 of 7

Etiologic diagnoses 2. Traumatic brain injury 2a 2 3 2b. If Present, does the subject have symptoms consistent with chronic traumatic encephalopathy? Yes 9 Unknown 2. Normal-pressure hydrocephalus 2a 2 3 22. Epilepsy 22a 2 3 23. CNS neoplasm 23b. Benign 2 Malignant 23a 2 3 24. Human immunodeficiency virus (HIV) 24a 2 3 25. Cognitive impairment due to other neurologic, genetic, or infectious conditions not listed above 25b. If Present, specify: 25a 2 3 Section 3 must be filled out for all subjects. Indicate presumptive etiologic diagnoses of the cognitive disorder and whether a given diagnosis is a primary, contributing, or non-contributing cause of the observed impairment, based on the clinician s best judgment. Select one or more diagnoses as Present; all others will default to Absent in the NACC database. Only one diagnosis should be selected as = Primary. For subjects with normal cognition: Indicate the presence of any diagnoses by selecting =Present, and leave the questions on whether the diagnosis was primary, contributing, or non-contributing blank. Subjects with positive biomarkers but no clinical symptoms of Alzheimer s disease, Lewy body disease, or frontotemporal lobar degeneration should not have these diagnoses selected as Present. Instead, the biomarker data from Section 2 can be used to identify the presence of preclinical disease. Condition 26. Active depression 26a 2 3 26b. If Present, select one: Untreated Treated with medication and/or counseling 27. Bipolar disorder 27a 2 3 28. Schizophrenia or other psychosis 28a 2 3 29. Anxiety disorder 29a 2 3 3. Delirium 3a 2 3 3. Post-traumatic stress disorder (PTSD) 3a 2 3 32. Other psychiatric disease 32a 2 3 32b. If Present, specify: UDS (v3., March 25) Initial Visit Form D: Clinician Diagnosis Page 6 of 7

33. Cognitive impairment due to alcohol abuse 33a 2 3 33b. Current alcohol abuse: Yes 9 Unknown 34. Cognitive impairment due to other substance abuse 34a 2 3 35. Cognitive impairment due to systemic disease/ medical illness (as indicated on Form D2) 35a 2 3 36. Cognitive impairment due to medications 36a 2 3 37. Cognitive impairment NOS 37a 2 3 37b. If Present, specify: 38. Cognitive impairment NOS 38a 2 3 38b. If Present, specify: 39. Cognitive impairment NOS 39a 2 3 39b. If Present, specify: UDS (v3., March 25) Initial Visit Form D: Clinician Diagnosis Page 7 of 7